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The anticancer drug doxorubicin penetrates into Langmuir monolaycrs containing phosphoinositides. Upon binding of doxorubicin to phospho- 
inositide-containing SUV, its fluorescence is self-quenched due to self-association. As compared to other anionic pllospholipids, as much as 2- to 
3-fold larger effects were obtained with PIP and PIP,, in mixtures of these lipids with DOPC. Doxorubicin competes efficiently with the non-penc- 
trating antibiotic neomycin for binding to PIP,. According to its penetration, specific binding of doxorubicin was half-maximal at S-15 PM. It 
is likely that also in biological membranes doxorubicin binds specifically to PIP and PIP,. 
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1. INTRODUCTION 
Doxorubicin and related anthracycline antibiotics are 
potent and widely-applied anticancer agents. They in- 
teract with DNA and topoisomerase II [i] as weli as 
with membranes. At least in model membrane systems, 
anionic phospholipids appear to be an important arget 
[2-61. Using NMR, fluorescence, X-ray and centrifuga- 
tion techniques, we have recently carried out a 
systematic omparison of the interactions between dox- 
orubicin and model membranes consisting of various 
phospholipids, including phosphatidic acid (PA) and 
phosphatidylserine [6]. The drug appeared to bind 
specifically to anionic phospholipids, to penetrate into 
the membrane and to induce a disordering of the acyl 
chains. Interactions between anthracyclines and anionic 
phospholipids involved in signal transduction are highly 
interesting in view of their possible effects on the 
regulation of cell proliferation [7]. It is therefore sur- 
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species of) phosphatidic acid, phophatidylcholine; PI, (bovine brain) 
phosphatidylinosito!; PIP, PIPI, PI-4-phosphate and PI-4,5-diphos- 
phate; SUV, small unilamellar vesicles prepared by sonication. 
prising that hardly anything is known about the interac- 
tions with (poly)phosphoinositides. We presently char- 
acterized the interactions of doxorubicin with model 
membranes containing phosphatidylinositol (PI), 
phosphatidylinositol-monophosphate (PIP) or -di- 
phosphate (PIP& 
2. MATERIALS AND METHODS 
l-[3-sn-phosphatidyll-D-myo-inosito! (PI), I-[3-sn-phosphatidyll- 
D-myo-inositol-4-phosphate (PIP) and I-[3-sn-phosphatidyll-D-myo- 
inosito!-4,5-diphosphate (PIPz) (a!! from bovine brain), 
l-stearoyl-2-arachidonoy1-3-sn-glycerophospha~idic ac d(SAPA) and 
neomycin sulfate (35% neomycin B. 5% neomycin C) were purchased 
from Sigma. Isolation and purification of other lipids were as describ- 
ed in [8-IO]. Lipid was determined on a phosphorus basis [ll]. Dox- 
orubicin was purchased from Aldrich (Belgium). Stock solutions were 
prepared shortly before use and were sllown by HPTLC [2] to be 
pure. Concentrations were determined as in [6]. A!! other chemicals 
were of analytical grade (Merck, Germany). A!! buffers contained 100 
mM NaC!, 10 mM PIPES, 5 mM EGTA. pH 7.4 (adjusted with 
NaOH). Monolayers were spread from solutions in CHCI3 or (in case 
of PIPz) CHC!J/CHXOH/HZO, 75:25:2 (v/v). The subphase was con- 
tinuously stirred; the surface pressure was recorded at room 
temperature with a platinum or paper (Schleicher and Schiil! nr. 595) 
Wilhelmy plate and a Cahn 2000 electrobalance. Measurements were 
performed both at constant area - [12] and at constant surface 
pressure [13] after equilibration of the drug in interaction with the 
monolayer. Small lipid aggregates were prepared by sonication ac- 
cording to [6] resulting in SUV or (in case of pure PIP or PIPz) 
micelles [ 141. Doxorubicin fluorescence was recorded in an Aminco 
SPF 500 fluorimeter. SUV (micelles) were titrated into a 
continuously-stirred cuvette containing 2.5 ml buffer with IOpM dox- 
orubicin at 25°C. Data were corrected for light scattering (usually 
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Fig. 1. Doxorubicin- or neomycin-induced increase of &face 
pressure in PIP2 monolayers. The agents corresponding to the 
abscissa were: (0). doxorubicin; (A) neomycin; (A), doxorubicin in 
the presence of 630pM neomycin, The data were obtained after full 
equilibration of the drug. Equilibrium was reached within a few 
minutes. The subphase (5 ml) further contained: 100 mM NaCI, 10 
mM PIPES, 5 mM EGTA, pH 7.4. The monolayer area was 4.9 cm’. 
negligible), drug dilution and light absorbtion (correction factor: 
IO’“” +Acm), AC, and Aem being the absorbances at the excitation and 
emission wavelengths: 490 and 594 nm, respectively). 
3. RESULTS AND DISCUSSION 
3. t . Penetration of doxorubicin into phosphoinositide 
monolayers 
At an initial surface pressure close to physiological 
values (30 mN.m-’ (c.f. (12,13,15]) and at constant 
monolayer area, doxorubicin elicited a large pressure 
increase in monolayers consisting of PIP2. An example 
is shown in Fig. 1. These data show that the drug 
penetrates into the monolayer. To assess the relative 
strength of binding, we compared the effect of dox- 
orubicin with that of the polyphosphoinositide-specific 
antibiotic neomycin [16]. No increase of surface pres- 
sure was induced by neomycin up to 630 PM (Fig. 1) 
showing that this hydrophilic drug did not penetrate. In 
agreement with the electrostatic nature of the binding 
of the drugs [6,16], neomycin competed efficiently with 
doxorubicin for binding to PIP2 (Fig. 1). At equal con- 
centrations of both drugs (630pM), the effect of doxo- 
rubicin was approx. 50% smaller than in the absence of 
neomycin, suggesting that the affinities of both drugs 
for PIP2 are comparable. Indeed the apparent affinity 
of doxorubicin emerging from drug penetration (Fig. 1) 
is comparable to the binding affinity of neomycin 
emerging from ref. [ 161. 
To investigate the specificity of doxorubicin-(po- 
ly)phosphoinositide interactions, we studied in a com- 
parative way the interactions with model systems con- 
taining PIP2, PIP, PI, DOPA, cardiolipin (the latter 
two for comparison with previous studies [2-61) and 
SAPA (having a similar fatty acid composition as 
bovine brain phosphoinositides [17]). In the ex- 
periments shown in Fig. 2, drug penetration was 
monitored by the drug-induced increase of the mono- 
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Fig. 2. Doxorubicin-induced area increase in monolayers at a con- 
stant surface pressure of 30 mN.m-‘. Data were obtained after full 
equilibration of the drug. A, pure lipids; PIP (at), PIP2 (O), PI (A), 
cardiolipin (A), SAPA (x), DOPA (+), DOPC ( q ). B, mixtures of 
80 mol Vo DOPC with 20 mol ‘70 of either: PIP (w), PIP2 (0) DOPA 
( +), cardiolipin (A), or PI (A). For comparison: pure DOPC (0). 
Note the different scalings in panels A and B. The subphase was 50 
ml, the starting monolayer area 32 cm’. Further conditions as in 
Fig. 1. 
layer area at constant surface pressure (30 mN.m-I), in 
analogy to [13]. Fig. 2A shows the data of pure anionic 
phospholipid monolayers and Fig. 2B those of mixtures 
of 20 molt% anionic phospholipid with 80 moI% 
DOPC. Of all anionic phospholipids tested, the largest 
drug-induced effects were elicited with PIP and PIP2, at 
least in the physiologically more relevant mixtures with 
DOPC (Fig. 2B). With pure DOPC, only a very small 
increase was obtained, in agreement with its low drug- 
binding capacity [6]. 
It is noteworthy that also on a molecular basis, PIP 
or PIP2 admixed with DOPC elicited the largest effects. 
We will shortly discuss this. The initial monolayer area 
was always the same. Thus, the total amount of lipid 
present in the monolayer varied according to the inverse 
of its molecular area. We determined the molecular 
area of the pure lipids (at 30 mN*m-‘): 0.94 (PIP2, 
PIP), 0.75 (PI), 0.69 (PA) and O.GB (DOPC) nm’. From 
the literature [5,18], a value of 1.25 nm2 can be obtain- 
ed for cardiolipin. The amount of lipid molecules in the 
monolayers can thus be calculated. On the basis of these 
data, and those of Fig. 2A (pure lipids), the average 
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drug-induced area increase per lipid molecule can be 
calculated: 0.64 (PIP), 0.44 (PIPz), 0.32 (PI), 0.48 (car- 
diolipin), 0.20 (SAPA), 0.17 (DOPA) and 0.04 (DOPC) 
nm’ at 100~M doxorubicin. In the lipid mixtures in the 
absence of drug, the overall area corresponded to the 
weighted average of the pure lipid components. The 
drug-induced increase of area per unit consisting of 1 
anionic phospholipid plus 4 DOPC molecules (Fig. 2B) 
was: 1.43 (PIP), 1.33 (PIP2), 0.54 (PI), 0.84 (car- 
diolipin) and 0.70 (DOPA) nm2 at IOOpM drug. Clear- 
ly, the largest effects were obtained with PIP and PIPz. 
The area increase in mixtures of DOPC and PIPz, 
PIP, PA, or cardiolipin (Fig. 2B) is larger than ex- 
pected on the basis of the effects obtained with the pure 
lipids (Fig. 2A). The DOPC molecules that surround 
the putative complex between the anionic phosphslipid 
aiid the drug [6] provide probably more room for 
penetration of the hydrophobic anthracyclinone moiety 
of the drug. Due to electrostatic effects, the initial 
degree of proton dissociation of pure PIP2, PIP and PA 
is probably lower than in mixtures with DOPC. This ef- 
fect might also contribute to the increased penetration 
of the drug in lipid mixtures containing DOPC, at low 
drug concentrations. At high concentrations, dox- 
orubicin is able to displace eventually both protons 
from the phosphorus of DOPA [6], and it is to be ex- 
pected that 3 and 5 protons can be displaced from PIP 
and PIP2 respectively, provided that sterical hindrance 
does not occur. 
Unfortunately, the overall drug-induced increase of 
area does not allow a precise calculation of the amount 
of penetrating drug, since the molecular surface of the 
anthracyclinone may vary from 0.1-0.7 nm2 depending 
on its orientation, and since the intrinsic packing of the 
lipids may depend on drug incorporation. 
Although PIP and PIP2 bind more doxorubicin than 
the other lipids, the apparent binding affinity of the 
various anionic phospholipids including the poly- 
phosphoinositides is similar. The concentration 
dependence of the doxorubicin-induced area increase 
(Fig. 2) displayed biphasic characteristics, in agreement 
with doxorubicin binding to large unilamellar vesicles 
prepared by extrusion [6]. The first phase was complete 
around IOOpM drug and was apparently half-saturated 
at 5-10pM drug. This is in reasonable agreement with 
the free drug concentrations (15-35 PM) previously 
shown [6] to saturate 50% of all potential binding sites, 
including non-penetrating sites, in anionic phospholipid 
bilayers. The high-affinity phase was not observed with 
DOPC (Fig, 2) and was specific for anionic phos- 
pholipids. The second phase (at 100-200 PM drug) 
could represent aspecific binding [3]. On the other 
hand, it does not contrast with the characteristics of 
doxorubicin binding to anionic phospholipid bilayers, 
which approaches saturation only around 500 PM free 
drug [6]. Analysis of the electrostatic redistribution of 
free drug close to the membrane surface (not shown, de 
Wolf, unpublished results) indicates that binding 
saturation is caused mainly by saturation of negatively- 
charged binding sites (charge neutralization), rather 
than by depletion of free drug at the membrane surface. 
In the absence of lipid, doxorubicin elicited a surFace 
pressure of only 0.2 mN*m-’ at 20 ,uM, or 14-15 
mN*m-’ at 250pM (not shown). Since these values are 
lower than the initial surface pressures of the lipid 
monolayers used presently, the above-described effects 
are indeed due to drug-lipid interactions. 
3.2. Doxotwbicin binding to phosphoinositide vesicles 
(sew-association) 
At sufficient drug density in the membrane, self- 
association of doxorubicin can occur at the membrane 
surface of anionic phospholipids [6], resulting in 
quenching of its fiuorescence [6]. The patterns of dox- 
orubicin seil’-qucndting shown in Fig. 3 demonstrate 
that such self-association also occurs in phospho- 
inositicle model membranes. At high SUV or micelle 
concentrations, as the majority of the drug is complex- 
ed, the self-quenching is reversed due to dilution of the 
drug in the membranes. This indicates that the binding 
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Fig. 3. Fluorescence of 1OpM doxorubicin as a function of SUV or 
micelle concentration (on a phosphorus basis). A, pure lipids; PI (A), 
DOPA (+), PIP2 (0), PIP (P). B, mixtures of 75 mol % DOPC with 
25 mol 070 of either: DOPA (+), PI (A), PIP (B), or PIP2 (0). For 
comparison: pure DOPC (0). Excitation was at 490 nm, emission at 
594 nm. The flurorescence yield, obtained after full equilibration of 
the drug, was normalized to the yield in the absence of lipid. 
Equilibration was reached within a few minutes. Further conditions 
as in Fig. 1. 
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is readily reversible and that the drug equilibrates be- 
tween all SUV (micelles). In analogy to the monolayer 
data, the largest quenching was obtained with PIP and 
PIP2. The difference with other anionic phosphoIipids 
(PI, DOPA) was especially large in the physiologically 
more relevant mixtures with DOPC. 
In general, the extent of quenching increased with the 
number of potential electrostatic binding sites (on the 
phosphorus atoms of the lipids). It was shown that dox- 
orubicin can displace protons from PA (p& 7.7) so as 
to disclose finally two electrostatic binding sites per 
phosphorus 161. According to the p& of PIP and PIP2 
[ 141, a similar phenomenon is expected for those lipids. 
PI induced a larger quenching than PA or (not shown) 
cardiolipin, in mixtures with DOPC. As discussed 
above, the average doxorubicin-induced increase of 
area per molecule lipid was smaller in mixed PI/PC 
monolayers than in PA/PC or cardiolipin/PC mono- 
layers. Possibly, a relatively larger fraction of the 
bound drug is self-associated at the surface of PI/PC 
than at the surface of PA/PC membranes. The origin 
of this effect is not known. In agreement with Fig. 2, 
Fig. 3 suggests that the apparent binding affinity of the 
various anionic phospholipids was similar. 
We showed previously that in phospholipid mem- 
branes, doxorubicin is present in at least two distinct 
pools: (1) penetrating fluorescent drug, and (2) (only at 
sufficient drug density in the membrane, reached only 
in anionic phospholipids) self-associated non-fluores- 
cent drug at the membrane surface 161. The present data 
indicate that such an organization occurs also in 
phosphoinositide-containing membranes and that PIP 
and PIP2 bind significantly more doxorubicin in either 
of the two membrane pools than the other anionic 
phospholipids. The quantitative differences between 
PIP2, PIP and other anionic phospholipids are especial- 
ly striking in mixtures of these lipids with DOPC and it 
is expected that also in the plasma membrane, dox- 
orubicin will specifically interact with poly- 
phosphoinositides. The physioIogica1 relevance of our 
observations i  supported by previous findings, which 
show that doxorubicin can affect phosphoinositide 
metabolism in cancer cells [19,20] and that monoclonal 
antibodies pecific for PIP2 can reverse mitogenesis and 
proliferation, specifically of ras-, erb B- or src- 
transformed cells [21,22]. 
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